Formulations for use in medical and diagnostic procedures
The present invention relates to formulations for use in medical or diagnostic procedures comprising a stabilizing agent alone or in combination with an osmotic agent. In one embodiment, the stabilizing agent is a natural hydrocolloid, preferably locust bean gum, and the osmotic agent is a sugar-based compound, preferably mannitol. The present invention also relates to formulations and methods for distending an anatomic segment. The present invention further relates to formulations and methods for delineating an anatomic segment on a diagnostic image, for example. The formulations of the present invention are especially suitable for use with diagnostic imaging procedures including, but not limited to magnetic resonance imaging (MR), computer assisted tomography (CT), and CT-PET (Position emission tomography), as well as other medical and therapeutic uses.
1. A formulation for use in preparing for a medical or diagnostic procedure comprising: an aqueous solution of 0.005% to 0.5% by weight of a natural hydrocolloid stabilizing agent and 1% to 8% by weight of a sugar-based compound, wherein the formulation alters an anatomic segment for performance of the medical or diagnostic procedure by facilitating the transfer of fluid or semi-fluid into the anatomic segment or facilitating the inhibition of fluid re-absorption in the atomic segment, and by modifying the viscosity of the fluid or semi-fluid in the anatomic segment, wherein the natural hydrocolloid stabilizing agent consists essentially of locust bean gum and the sugar-based compound is selected from the group consisting of mannitol, sorbitol, and combinations thereof.
2. The formulation of claim 1 , comprising about 0.05% to 0.5% by weight of the natural hydrocolloid.
3. The formulation of claim 1 , further comprising natural or artificial flavoring.
4. A method of performing a diagnostic imaging procedure comprising administering the formulation of claim 1 .
5. The method of claim 4 , wherein the formulation is administered orally.
6. The method of claim 4 , wherein the formulation is administered via intubation.
7. The method of claim 4 , wherein said diagnostic imaging procedure further comprises imaging of the lymph nodes, vasculature system, pancreas, liver, appendix, gall bladder or spleen.
8. The method of claim 4 , wherein said diagnostic imaging procedure further comprises imaging of the stomach.
9. The method of claim 4 , wherein said diagnostic imaging procedure further comprises imaging of the gastrointestinal tract.
10. The method of claim 4 , wherein said diagnostic imaging procedure comprises a technique selected from the group consisting of X-ray imaging, MR, CT, SPECT, PET and CT-PET.
11. The method of claim 10 , further comprising the step of imaging the gastrointestinal tract.
12. The method of claim 10 , further comprising the step of imaging the small intestine.
13. The method of claim 10 , further comprising the step of imaging the colon.
14. The method of claim 10 , further comprising the step of imaging the pancreas.
15. The method of claim 10 , further comprising the step of imaging the duodenum.
16. The method of claim 10 , further comprising the step of imaging the cecum.
17. The method of claim 10 , further comprising the step of imaging the bowel.
18. The method of claim 10 , further comprising the step of imaging the large intestine.
19. The method of claim 10 , further comprising the step of imaging the jejunum.
20. The method of claim 10 , further comprising the step of imaging the ileum.
21. The method of claim 10 , further comprising the step of imaging the appendix.
22. The method of claim 10 , further comprising the step of imaging the pancreas is imaged.
23. The method of claim 10 , further comprising the step of imaging the duodenum.
24. The method of claim 10 , further comprising the step of imaging the sigmoid.
25. The method of claim 10 , further comprising the step of imaging the rectum.
26. The method of claim 10 , further comprising the step of imaging the stomach.
27. The formulation of claim , 1 wherein the sugar-based compound is mannitol.
28. The formulation of claim 27 , comprising about 0.25% by weight of the hydrocolloid and about 3% by weight mannitol.
29. A formulation comprising about 0.005% to 0.5% by weight locust bean gum and about 1% to 8% by weight mannitol.